The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Bcl-2 inhibitor APG-2575 receives FDA orphan drug designation for the treatment of AML

Jan 11, 2021
Share:

On January 4, 2021, APG-2575 was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute myeloid leukemia.1

APG-2575, a novel Bcl-2 inhibitor, can be administered orally and is being evaluated in a number of hematological malignances through international Phase Ib/II trials. The selective inhibition of Bcl-2 is hypothesized to reinstate functional apoptosis in malignant cells.2 APG-2575 has also received orphan drug designation for the following indications:

  • Waldenström’s macroglobulinemia
  • Chronic lymphocytic leukemia
  • Multiple myeloma

  1. PRNewswire. Ascentage Pharma announces its 9th orphan drug designation from the US FDA in 2020, setting a record for Chinese biopharmaceutical companies. https://www.prnewswire.com/news-releases/ascentage-pharma-announces-its-9th-orphan-drug-designation-from-the-us-fda-in-2020-setting-a-record-for-chinese-biopharmaceutical-companies-301200596.html. Published Jan 4, 2021. Accessed Jan 7, 2021.
  2. PRNewswire. Ascentage Pharma's Bcl-2 Inhibitor APG-2575 granted orphan drug designation by the FDA for the treatment of chronic lymphocytic leukemia. https://www.prnewswire.com/news-releases/ascentage-pharmas-bcl-2-inhibitor-apg-2575-granted-orphan-drug-designation-by-the-fda-for-the-treatment-of-chronic-lymphocytic-leukemia-301124971.html. Published Sep 7, 2020. Accessed Jan 7, 2021.

Share:
More about...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox